Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262828 | 0.88 | AKR1B1 (0.46) | PTGDR2CA12CA1CA2CA9 | |
| SCHEMBL4258971 | 0.87 | TP53 (0.45) | PTGDR2ADAMTS5MAPTTP53AKR1B1 | |
| SCHEMBL4262827 | 0.86 | AKR1B1 (0.47) | PTGDR2ADAMTS5MAPTTP53AKR1B1 | |
| SCHEMBL4257897 | 0.86 | MAPT (0.40) | PTGDR2MAPTTP53AKR1B1 | |
| SCHEMBL4259885 | 0.85 | ADAMTS5 (0.52) | ADAMTS5MAPTTP53 | |
| SCHEMBL4262836 | 0.84 | HSP90AA1 (0.40) | ADAMTS5ACHEMAPTTP53AKR1B1 | |
| SCHEMBL4266332 | 0.84 | ADAMTS5 (0.40) | ADAMTS5ACHEMAPTTP53AKR1B1 | |
| SCHEMBL4260823 | 0.83 | HSP90AA1 (0.52) | ADAMTS5CA12CA1CA2CA9 | |
| SCHEMBL4258238 | 0.83 | ADAMTS5 (0.39) | ADAMTS5ACHEMAPTTP53AKR1B1 | |
| SCHEMBL4159534 | 0.82 | ADAMTS5 (0.42) | ADAMTS5MAPTTP53AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | PTGDR2 193/4885ADAMTS5 2269/4885CA12 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.